GlassScriptPhysician profile
Nasem Sayegh
NPI 1720043920
$14,584.80
in general payments reported to CMS, 2019-2025
58 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what 91% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
See the full distribution for Geriatric Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,878 · 2020: $1,654 · 2021: $2,698 · 2022: $3,750 · 2023: $2,065 · 2024: $1,392 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,538 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,538.19 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,040.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,348.62 | 2020-2025 | Vraylar, Ubrelvy, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $853.04 | 2019-2025 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $772.73 | 2023-2025 | Gemtesa |
| Abbott Laboratories | $665.05 | 2021-2025 | Freestyle Libre, Jeti |
| Valeritas, INC. | $487.19 | 2019 | |
| Cmp Pharma, INC. | $433.25 | 2022-2023 | Tadliq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.58 | 2019-2024 | Jardiance |
| Amgen INC. | $394.87 | 2021-2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $384.92 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $362.50 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $356.12 | 2021-2025 | |
| Astellas Pharma US INC | $336.16 | 2019-2023 | Veozah |
| Janssen Pharmaceuticals, INC | $322.80 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $317.17 | 2022-2025 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasem Sayegh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.